The provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry has posted another set of full year results demonstrating solid growth with total income up 53% to £783k, marginally ahead of our £750k expectation for FY June 2019. Net losses were down 43% to £104k and cash burn was also modest with the Company ending the period with cash balances of £405k (2018: £572k)
30 Sep 2019
Growth fuelled by existing and new customers
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Growth fuelled by existing and new customers
Physiomics Plc (PYC:LON) | 1.3 0 0.0% | Mkt Cap: 1.76m
- Published:
30 Sep 2019 -
Author:
Derren Nathan -
Pages:
7
The provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry has posted another set of full year results demonstrating solid growth with total income up 53% to £783k, marginally ahead of our £750k expectation for FY June 2019. Net losses were down 43% to £104k and cash burn was also modest with the Company ending the period with cash balances of £405k (2018: £572k)